Can I take only one pill when taking lenvatinib/lenvatinib? What are the effects?

Lenvatinib is a prescription drug with clear dosage guidelines and must be taken strictly in accordance with your doctor's instructions. Each patient's daily dose of medication is different based on their specific cancer type (kidney cancer, liver cancer, thyroid cancer) , weight, liver and kidney function status, and combined treatment plan. Among several common clinical indications, the recommended starting dose of lenvatinib can range from 8 mg to 24 mg, and is usually taken continuously once daily. Drug packaging specifications are usually 4 mg and 10 mg capsules. In order to achieve flexible dosage combinations, doctors will adjust the specific number of drug particles according to the treatment plan. Simply taking one pill, if it is not arranged by a doctor for a specific dose, is very likely to result in an insufficient dose, thus affecting the therapeutic effect.

If the patient reduces the dose without authorization, for example, taking only one 10 mg capsule per day, when the dose should be 18 mg or higher, the drug may not be able to achieve sufficient blood concentration, resulting in a weakening of the inhibitory effect of the targeted pathway, and even poor disease control or early onset of drug resistance. The reason why lenvatinib needs to be precisely adjusted according to the dose is that its mechanism of action involves multiple signaling pathways, and its efficacy is closely related to its concentration. In addition, although lenvatinib is a targeted drug, it may still cause adverse reactions including hypertension, proteinuria, fatigue, anorexia and other adverse reactions. Overdosage may lead to increased toxicity. Therefore, individual tolerance and efficacy balance must also be considered when reducing the dose rather than discretionary decision-making.

It should be emphasized that the pharmacokinetic characteristics of lenvatinib show that its blood concentration needs to reach a stable level to effectively inhibit the activity of tumor-related kinases. Therefore, irregular medication or frequent dose adjustments will interfere with the treatment rhythm, thereby reducing the overall treatment success rate.

Reference materials:https://www.lenvima.com/